Free Trial

Orgenesis (ORGS) Competitors

Orgenesis logo
$1.39 -0.21 (-13.13%)
As of 01/17/2025 03:42 PM Eastern

ORGS vs. LSTA, CGTX, CVM, INKT, KALA, MRNS, UBX, DARE, VRCA, and MTEX

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Lisata Therapeutics (LSTA), Cognition Therapeutics (CGTX), CEL-SCI (CVM), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), Unity Biotechnology (UBX), Daré Bioscience (DARE), Verrica Pharmaceuticals (VRCA), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.

Orgenesis vs.

Orgenesis (NASDAQ:ORGS) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 304.31%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Orgenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Lisata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lisata Therapeutics has lower revenue, but higher earnings than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$530K12.59-$55.36MN/AN/A
Lisata TherapeuticsN/AN/A-$20.84M-$2.51-1.48

Orgenesis has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Lisata Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Lisata Therapeutics N/A -51.19%-45.16%

Lisata Therapeutics received 13 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 93.33% of users gave Lisata Therapeutics an outperform vote.

CompanyUnderperformOutperform
OrgenesisOutperform Votes
1
100.00%
Underperform Votes
No Votes
Lisata TherapeuticsOutperform Votes
14
93.33%
Underperform Votes
1
6.67%

In the previous week, Lisata Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Lisata Therapeutics and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Lisata Therapeutics Neutral

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lisata Therapeutics beats Orgenesis on 10 of the 14 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.67M$6.50B$5.34B$9.12B
Dividend YieldN/A2.95%5.37%4.01%
P/E RatioN/A4.3657.4613.13
Price / Sales12.59310.771,272.2275.82
Price / CashN/A22.8736.6632.72
Price / Book-0.214.964.884.58
Net Income-$55.36M$154.90M$118.05M$224.83M
7 Day Performance-7.95%1.35%1.45%2.37%
1 Month Performance6.92%0.41%2.50%4.40%
1 Year PerformanceN/A3.08%25.79%20.10%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
N/A$1.39
-13.1%
N/AN/A$6.67M$530,000.000.00150
LSTA
Lisata Therapeutics
3.0146 of 5 stars
$3.67
-1.6%
$15.00
+308.7%
+25.8%$30.81MN/A-1.4630Positive News
CGTX
Cognition Therapeutics
2.5288 of 5 stars
$0.74
-2.7%
$8.30
+1,021.5%
-70.4%$30.75MN/A-0.7620Gap Down
CVM
CEL-SCI
N/A$0.41
-2.4%
N/A-83.4%$30.70MN/A-0.7243Gap Up
INKT
MiNK Therapeutics
2.4589 of 5 stars
$0.77
+5.9%
$6.50
+739.9%
+0.0%$30.67MN/A-1.9830Gap Up
KALA
KALA BIO
4.1002 of 5 stars
$6.55
-3.8%
$15.00
+129.0%
-2.3%$30.20M$3.89M-0.5330Negative News
MRNS
Marinus Pharmaceuticals
4.606 of 5 stars
$0.54
+0.8%
$4.79
+784.4%
-94.4%$29.88M$31.47M-0.22110Analyst Forecast
UBX
Unity Biotechnology
4.4282 of 5 stars
$1.72
-3.9%
$7.33
+326.4%
+3.6%$28.98M$240,000.00-1.3160
DARE
Daré Bioscience
1.2681 of 5 stars
$3.33
+6.7%
$24.00
+620.7%
-10.2%$28.97M$1.88M-5.6430News Coverage
Positive News
VRCA
Verrica Pharmaceuticals
4.0806 of 5 stars
$0.64
-3.8%
$9.50
+1,396.1%
-88.5%$28.96M$9.21M-0.3540
MTEX
Mannatech
0.4386 of 5 stars
$15.17
+1.3%
N/A+33.6%$28.60M$121.55M-18.73250Analyst Forecast
Gap Down

Related Companies and Tools


This page (NASDAQ:ORGS) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners